Giovanni Caforio, Bristol Myers Squibb CEO (Nicolas Messyasz/Sipa via AP Images)

Bris­tol My­ers turns at­ten­tion to new prod­ucts in wake of Revlim­id patent loss

Bris­tol My­ers Squibb CEO Gio­van­ni Caforio is shift­ing his fo­cus to new­er prod­ucts as gener­ic sales con­tin­ue to gnaw at the com­pa­ny’s block­buster myelo­ma drug …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.